RCM
VRTX icon

Riverhead Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Riverhead Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2.76M Buy
16,303
+4,595
+39% +$813K 0.1% 258
2019
Q2 		$2.15M Buy
11,708
+2,274
+24% +$398K 0.08% 328
2019
Q1 		$1.74M Buy
9,434
+1,102
+13% +$204K 0.07% 341
2018
Q4 		$1.38M Sell
8,332
-662
-7% -$115K 0.06% 360
2018
Q3 		$1.73M Buy
8,994
+90
+1% +$16K 0.06% 346
2018
Q2 		$1.51M Buy
8,904
+1,713
+24% +$266K 0.06% 364
2018
Q1 		$1.17M Buy
7,191
+650
+10% +$106K 0.05% 388
2017
Q4 		$980K Buy
6,541
+1,062
+19% +$157K 0.04% 438
2017
Q3 		$833K Sell
5,479
-1,350
-20% -$203K 0.04% 450
2017
Q2 		$880K Sell
6,829
-708
-9% -$85.2K 0.04% 415
2017
Q1 		$824K Buy
7,537
+2,158
+40% +$190K 0.05% 408
2016
Q4 		$396K Hold
5,379
– – 0.02% 556
2016
Q3 		$469K Sell
5,379
-20,552
-79% -$1.94M 0.03% 480
2016
Q2 		$2.1M Sell
25,931
-3,400
-12% -$294K 0.07% 305
2016
Q1 		$2.33M Sell
29,331
-12,268
-29% -$1.11M 0.03% 490
2015
Q4 		$5.24M Buy
41,599
+900
+2% +$109K 0.08% 318
2015
Q3 		$4.24M Sell
40,699
-1,263
-3% -$162K 0.07% 330
2015
Q2 		$5.18M Sell
41,962
-941
-2% -$119K 0.08% 312
2015
Q1 		$5.06M Buy
42,903
+513
+1% +$61.5K 0.08% 304
2014
Q4 		$5.04M Sell
42,390
-4,615
-10% -$520K 0.08% 297
2014
Q3 		$5.28M Sell
47,005
-917
-2% -$87.3K 0.09% 273
2014
Q2 		$4.54M Buy
47,922
+3,255
+7% +$228K 0.09% 286
2014
Q1 		$3.16M Sell
44,667
-7,691
-15% -$609K 0.07% 314
2013
Q4 		$3.89M Buy
52,358
+20,358
+64% +$1.42M 0.1% 262
2013
Q3 		$2.43M Sell
32,000
-5,000
-14% -$398K 0.08% 263
2013
Q2 		$2.96M Buy
+37,000
New +$2.72M 0.1% 229

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Riverhead Capital Management's VRTX Position: Q3 2019 in Review

Riverhead Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 39% in Q3 2019, buying an estimated $813K and bringing the position to 16,303 shares worth $2.76M. The position accounts for 0.1% of the portfolio, ranked #258.

Riverhead Capital Management first reported a position in VRTX in Q2 2013 and has held it in 26 quarters since. The position peaked at $5.28M in Q3 2014. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Riverhead Capital Management held 16,303 shares of Vertex Pharmaceuticals worth $2.76M as of Q3 2019.
  • Riverhead Capital Management bought 4,595 Vertex Pharmaceuticals shares in Q3 2019, an estimated $813K.
  • Vertex Pharmaceuticals made up 0.1% of Riverhead Capital Management's portfolio in Q3 2019, its #258 holding.
  • Riverhead Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Riverhead Capital Management's Vertex Pharmaceuticals position peaked at $5.28M in Q3 2014.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.